|Bid||23.57 x 800|
|Ask||23.59 x 900|
|Day's Range||23.11 - 23.90|
|52 Week Range||5.31 - 26.77|
|Beta (3Y Monthly)||2.89|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 7, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||26.96|
SAN FRANCISCO, April 23, 2019 /PRNewswire/ -- Invitae Corporation (NVTA), a leading genetics company, today announced that it will report its first quarter 2019 financial results on Tuesday, May 7, 2019 and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights. The dial-in numbers for the conference call are (866) 393-4306 for domestic callers and (734) 385-2616 for international callers, and the reservation number for both is 3435689. Invitae Corporation (NVTA) is a leading genetics company, whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people.
Top-line growth and solid show by Population Health, Revenue Cycle and IT Works are likely to aid Cerner (CERN) in Q1. However, expected decline in bookings is likely to be a dampener.
It's the same action that we've had for much of this week. Stocks press lower near the open only to recover by lunch and push higher in the afternoon. The gains aren't remarkable, but the bulls' resilience is something to take note of. The sector rotation underway also remains astounding. On that note, let's look at a few must-see stock charts for Monday.Remember, the U.S. markets are closed tomorrow for Good Friday. Must-See Stock Charts for Monday 1: InvitaeInvestorPlace - Stock Market News, Stock Advice & Trading TipsAbove is the daily chart for Invitae (NASDAQ:NVTA) and below is the weekly. This morning on Twitter, I pointed out that NVTA could post a sweet bounce, but I didn't think it would be this vicious.Shares ripped off of the 10-week and 50-day moving averages, gaining almost 8% from today's lows. This is definitely one to watch next week to see if the momentum can continue.I would have loved to buy NVTA at $21, but over $22 and NVTA could be primed for more upside. Must-See Stock Charts for Monday 2: BlackstoneBlackstone (NYSE:BX) delivered a strong earnings report and announced it will switch from a partnership to a corporation. Anyone ever own BX before? I have and waiting for a K-1 form that doesn't usually come until April is a pain the you-know-what. Switching to a corporation will make sense for the business and potentially make its stock more attractive to investors. Plus it has a monster yield.Could that cause a further breakout? Perhaps. Over $38 is encouraging for more upside, with long-term uptrend resistance not playing a role until the $40s. Below $38 and bulls may need to let BX reset. Above and it's okay. Must-See Stock Charts for Monday 3: Canopy GrowthAn explosive couple of days have put Canopy Growth (NYSE:CGC) back on the radar. But if the strong rally on Wednesday and Thursday proved anything to me, it's how tough of resistance $38 is.I'm watching CGC next week to see if the stock can pierce this level. If it can, it would be very bullish to see CGC find $38 as support. As long as it holds $44, CGC should be good on the long side. Must-See Stock Charts for Monday 4: Union PacificBetter than expected earnings propelled Union Pacific (NYSE:UNP) to new 52-weeks high on Thursday. There sure are a lot of bearish calls out there despite so many names hitting new annual highs.Anyway, as long as UNP stock holds $160 next week, the bull case still looks strong. A pullback to the 10-week moving average that holds as support can be bought, while a run to channel resistance is possible over the intermediate term. Must-See Stock Charts for Monday 5: PinterestThe Pinterest (NYSE:PINS) and Zoom (NASDAQ:ZM) IPOs got off to a much better start than Lyft (NASDAQ:LYFT) did, currently up 30% and 75% on the day, respectively.For investors, there a lot less volatile plays out there than these fresh IPOs. But if you have to play them, investors at least have the IPO day range to work with. A red-to-green open on Monday could draw in more buyers for PINS, while a push through the highs could ad even more momentum to the name. * The Jobs Report Isn't an Effective Metric for the U.S. Economy If it's too short term for you, don't have any regrets about giving it more time to base. (Here are 13 things to know about the Pinterest IPO).Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret Kenwell is long NVTA. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 5 Dividend Stocks Perfect for Retirees * 7 Reasons the Stock Market Rally Isn't Over Yet * 10 S&P 500 Stocks to Weather the Earnings Storm Compare Brokers The post 5 Must-See Stock Charts for Monday: CGC, PINS, NVTA, UNP, BX appeared first on InvestorPlace.
Investors are always looking for growth in small-cap stocks like Invitae Corporation (NYSE:NVTA), with a market cap of US$2.2b. However, an important fact which most ignore is: how financially healthy is the business...
Stock investors seeking even bigger returns than the 2019 bull rally might look at five ETFs that have already gained at least 40% year-to-date, approaching triple the 15% pace of the S&P 500. The winners ...
A better-than-expected jobs report has stocks gravitating higher on Friday, as the S&P 500 continues to go higher. Let's see how our top stock trades are setting up after another broad market rally. Top Stock Trades for Tomorrow 1: SpotifyDespite the noise around Apple (NASDAQ:AAPL) topping Spotify (NYSE:SPOT) for music subscriptions, the stock is actually trading pretty well.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 Medical Marijuana Stocks to Cure Your Portfolio SPOT is not only holding the 20-day and 50-day moving averages, but is also holding its breakout point over short-term downtrend resistance. Bulls have a low-risk entry at this point, with a potential $10 move up to the February highs and the 200-day moving average. Top Stock Trades for Tomorrow 2: Occidental PetroleumDepending on how one draws their trendlines, Occidental Petroleum (NYSE:OXY) is either breaking out or almost breaking out of its recent range.As long as oil prices hold up, OXY and the bunch can likely continue higher (here's our trade in Exxon Mobil (NYSE:XOM) that's working on Friday too).A reasonable target for OXY? The 200-day moving and the $73 to $74 level. On the downside, a close back below $67 puts OXY back in its prior range, although the 50-day has been solid support. Top Stock Trades for Tomorrow 3: InvitaeInvitae (NASDAQ:NVTA) has become a fascination among traders, as the high-flyer continues to make wild moves. Even though it was up 7% at one point on Friday, there was talk about an even further rally to new highs north of $26.With the intraday pullback, that didn't really work out for NVTA, but the bulls are still doing okay. Shares continue to grind up this 20-day moving average, with Invitae continually pulling back off $25 resistance.Short of a market-wide correction, this sets up the thesis of, "the more times a level is tested, the more likely it is to break." We said any pullbacks into this $20 to $21 area will be bought up and that's panned out thus far.So what now? Bulls can keep riding this momentum along the 20-day and look for a breakout over $25. Over $26 and this thing could really fly. Below uptrend support, the 20-day and $21, and we'll need to re-evaluate. Top Stock Trades for Tomorrow 4: JD.comEarlier this week we highlighted Alibaba (NYSE:BABA) and boy has this one been trading really well, now at $185. Now it must be JD.com's (NASDAQ:JD) turn, as this one continues to climb too.It's knocking on $32 and wants higher. Should it get over this mark, it could run up toward $35. It might be too greedy to ask for another pullback, given that investors could have nabbed this one below $30 just a few days ago. However, keep an eye on $32. If shares push through it, see if $32 acts as support. That's a great buying chance, as would a pullback into the $29 area. Top Stock Trades for Tomorrow 5: StarbucksStarbucks (NASDAQ:SBUX) has been an absolute beast. It was up in the fourth quarter and has continued higher in Q1 too. Not many names can say that, as SBUX is now up more than 56% from its summer lows.With this strong of a trend, it's hard to be a seller, even after such a big move. Shares are knocking on $75, wanting to push up. If they rally this into earnings later this month, it's hard to imagine much upside being left. That said, pullbacks into the 20-day are safe buying opportunities for now. * Critical Levels to Watch in 3 Marijuana Stocks See that SBUX stays above $72.Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret Kenwell is long SBUX, AAPL and NVTA. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 9 Stocks That Would Be Hurt By a Mexico/U.S. Border Closure * 7 A-Rated Healthcare Stocks for Industry Expansion * 10 Stocks That Every 30-Year-Old Should Buy and Hold Forever Compare Brokers The post 5 Top Stock Trades for Monday: JD, NVTA, SBUX, SPOT, OXY appeared first on InvestorPlace.
- Data presented at The American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting - SAN FRANCISCO , April 2, 2019 /PRNewswire/ -- Researchers from Invitae (NYSE: NVTA), ...
Man do I kick myself on Twilio (NYSE:TWLO). Because of the limited-supply stock offering we got in the IPO, shares exploded to the upside. After rallying from sub-$30 to $65, shares eventually cooled off again. Investors had a chance to scoop up Twilio stock under $30 for about 13 months, essentially all of 2017.Source: John Britton via FlickrThat was the time to strike and that's why I'm kicking myself. Shares last traded below that threshold in February of 2018. Now up near $125, bulls who have been holding the name have seen a massive payoff.Investors will likely never get a chance to buy this one back near $25 to $30 again, but that doesn't mean they won't get a buying opportunity. Should the broader market come under pressure again in the form of a correction, TWLO stock will almost surely go on sale.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 8 Genomic Testing Stocks That Can Ease the Sting of Theranos For instance, during the fourth-quarter correction, Twilio stock was changing hands at $65, roughly 50% below current levels. Let's look at the charts a bit more. Trading TWLO Stock Click to EnlargeThe chart is a little zoomed out for my preference, but it highlights everything we need in TWLO stock.The first kick-yourself moment came back in February 2018, when TWLO stock went into full-blown breakout mode. Even those who waited until this moment -- buying at $35 instead of $25 -- have reaped massive returns. Those who missed this opportunity weren't left completely in the dust though. They had another chance as well.Shares of Twilio broke down in October, but buying it seemed too risky. That's fine. However, in November, shares put in a higher low, a bullish technical development, and more important, the stock did so after reporting earnings. The report was a blowout, sending the stock from a $70 to $100 in just two days.Yet, like Nike (NYSE:NKE), Roku (NASDAQ:ROKU) and countless others who reported strong reports and were unreasonably sold off during the correction, TWLO stock too found itself lower. Less than two weeks after that report, shares were back to its pre-earnings levels.That was a perfect chance to buy Twilio stock for those that missed it the first time. That's where comes kick-yourself moment No. 2 comes into play if you didn't pull the trigger (don't worry, I'm in the club too).So why am I going through all of this? After all, it was last quarter. Because this price action could repeat itself should we get another market correction. I don't know if we'll see $65 anytime soon and to be clear, I'm not looking for the markets to retest the December lows. But maybe we get another chance at Twilio near $100. Perhaps $90 and even $75 could be on the table in a larger correction. Evaluating Twilio StockOn big rallies, investors should consider lightening up on some of their positions, creating cash for the eventual pullback. These pullbacks should create opportunities for investors looking to get back into the market's best growth names.Twilio clearly has a long runway of growth, but don't mistake this for a cheap stock. With its $15.5 billion market cap, TWLO stock trades at roughly 14 times this year's sales. That said, analysts expect revenue to grow 65% this year to $1.08 billion and another 32% next year.Further, the company is expected to earn 10 cents per share this year and 27 cents per share next year. With Twilio's lack of profitability, there's no point in trying to value it on an earnings basis.Fundamentalists will quickly critique that observation, but just because there's no profitability doesn't mean the company isn't worth investigating. After all, Amazon (NASDAQ:AMZN) and Netflix (NASDAQ:NFLX) have returned thousands of percent over the last decade and trust me, those companies had plenty of profit critics over that span. Heck, even Twilio stock is up 200% over the past 12 months despite its relatively empty bottom line.In fact, many of the market's biggest winners lately, Roku, The Trade Desk (NASDAQ:TTD), Invitae (NASDAQ:NVTA), Okta (NASDAQ:OKTA), etc., aren't yet profitable. But enterprise software has been on fire and for that, Twilio stock is at least deserving of a deeper look on a larger market pullback.Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret Kenwell is long NVTA, ROKU and AMZN. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 8 Genomic Testing Stocks That Can Ease the Sting of Theranos * 4 Pot Stocks That Could Be Fizzling Out * 7 Mid-Cap Growth Stocks That Could Be the Next Amazon or Netflix Compare Brokers The post Twilio Stock Is a Must Buy on Any Market Correction appeared first on InvestorPlace.
When investors are looking for future growth candidates, they often think of names like Netflix (NASDAQ:NFLX), Amazon (NASDAQ:AMZN) or Salesforce (NYSE:CRM). "But I missed most of the rally," they say. That's because they're looking at these companies after they've gone from a $10 billion valuation to a $100 billion. Finding these stocks when they are mid-cap growth stocks can be a portfolio-changing phenomenon.I'm not trying to play up mid-cap growth stocks too much. After all, many times these companies have little to no profits and the stocks have high valuations. Further, their price action tends to be super volatile, both on the upside and the downside. They also aren't mature, meaning their business models can either deteriorate or strengthen over time, depending on how management adapts to new challenges. * 8 Genomic Testing Stocks That Can Ease the Sting of Theranos It makes picking names in this group hard, but quite rewarding when investors hit a few home runs. Let's look at seven mid-cap growth stocks now to see which ones could pay off big-time in the future. Mid-cap stocks are those that have a valuation between $2 billion and $10 billion.InvestorPlace - Stock Market News, Stock Advice & Trading Tips The Trade Desk (TTD) Click to EnlargeSheesh, what a monster this one has been. The Trade Desk (NASDAQ:TTD) has rallied from $150 to $200 in about a month and is up about 100% from its December lows. Talk about explosive right?I barely missed my fill in this one in late December and I'm pretty darn disappointed as a result. On the plus side, I did get the next two names on this list. In any regard, let's talk about TTD, because the growth here is simply too impressive to ignore.When TTD reported earnings in February, it beat on earnings and revenue estimates. In fact, earnings of $1.09 per share came in a full 30 cents per share -- or almost 40% -- ahead of estimates. Revenue growth accelerated to 56% year-over-year and guidance for the the next quarter and full year came in ahead of expectations.That's music to growth investors' ears. Beat-and-raise quarters are key to driving a growth stock higher. From CEO Jeff Green: "In the coming year, we will continue to make aggressive investments in high growth areas such as Connected TV, data, and global expansion, including in China."The company is free cash flow positive, which is a another huge plus for a mid-cap growth stock. Analysts expect about 35% revenue growth this year and 28% next year. Invitae (NTVA) Click to EnlargeThis one has been a monster so far this year; Invitae (NASDAQ:NVTA) is already up more than 100% in 2019. Simply put, this company has serious momentum in its business right now. Luckily, InvestorPlace readers had this one on their radar at $15.In February, NVTA beat already-heightened expectations as it grew revenue almost 80% year-over-year. After the stock's explosive rally as a result, Invitae took advantage with a secondary offering, which was promptly bid up as investors rushed to get in this name below $20.The recent selloff in the markets has weighed on NVTA, which almost hit $26 just a few sessions ago. Should it get back down the $20 to $21 level, I suspect it will bring buyers back in. So why is NVTA attracting so many investors? Because the company has a ton of runway right now. Estimates call for 50% revenue growth this year and 47% next year. * 5 Cheap Dividend Stocks to Buy Now Even after the big run, its market cap sits at just $2 billion. M&A isn't necessarily out of the picture at that range either, even though the company is not yet profitable. That will come soon enough. Roku (ROKU) Click to EnlargeAlong with NVTA, Roku (NASDAQ:ROKU) has been another massive 2019 winner, up 108% so far. Obviously this type of momentum is hard to maintain, but for long-term investors it's a promising start.The stock came up just short of making new all-time highs earlier this month. However, I wouldn't be surprised if it happens at some point in 2019.Many argue that Roku stock is overvalued and based on its current financials -- and it is. Roku is not yet profitable, while sales are forecast to top $1 billion for the first time this year. Next year, expectations call for $1.36 billion in sales. Does that justify a $7 billion market cap?Maybe not to some. But investors are forward looking and they can see what's in Roku's future.That said, Roku is arguably the best-positioned company to take advantage of the streaming revolution. This secular shift will carry on for years and years, paving the way for tech companies to generate serious cash flow. In Roku's case, it will eventually be profitable and go from free cash flow neutral to free cash flow positive. Its balance sheet is actually pretty strong too, with no debt, while total current assets of ~$433 million easily outweigh total current liabilities of $194 million.If you don't doubt streaming, then you shouldn't doubt Roku. Canada Goose (GOOS) Click to EnlargeWhen investors think of mid-cap growth stocks to buy, technology is generally at the forefront. But that doesn't mean we should exclude companies like Canada Goose (NYSE:GOOS).Get this. On February 14th, GOOS reported a blowout quarter. GAAP earnings of 93 cents a share came in 32 cents -- or 52% -- ahead of analysts expectations. Revenue of $399 million grew 50% year-over-year and blew past estimates of ~$266 million by 50%. This was a massive beat!But it gets better. Gross margins improved 80 basis points to 64.4% and guidance was robust. Management expects its revenue growth rate in the mid-to-high thirties and for earnings in the mid-to-high forties. And notably, GOOS is profitable.For whatever reason though, investors want nothing to do with it. Perhaps it's concern over the global economy or that only so many customers will buy such expensive products. Those reasons are valid, but I wouldn't throw out GOOS until it gives me a good reason to. * 3 Casino Stocks to Bet On Maybe we can get this one on a discount as its charts are struggling to buoy the name. Alteryx (AYX) Click to Enlarge Alteryx (NYSE:AYX) doesn't get a ton of attention out there, quietly garnering a market cap of just $5 billion. The downside to this name is that the stock price can be highly volatile. But that's the price investors pay when it comes to performance, With AYX up almost 40% so far this year and more than 130% over the past 12 months.Alteryx "operates a self-service data analytics software platform that enables organizations to enhance business outcomes and the productivity of their business analysts, data scientists, and citizen data scientists worldwide."That kind of business model should have a long runway in this data-rich environment. Analysts are optimistic too, calling for almost 70% revenue growth this year. However, those estimates taper off to "just" 34% next year. While these estimates can always increase, it does cause some concern given AYX's valuation. This name trades at almost 15 times this year's revenue estimates. On the plus side, it is free cash flow positive.I like this name, but it's going on the back burner until we can get a better price. At its low in October, AYX was trading hands near $42.50. Just earlier this month, Alteryx was down at $65. Volatility can either work in investors' favor or against them. Let's make it the former. Okta (OKTA) Click to EnlargeStaying in the tech sector, Okta (NASDAQ:OKTA) has been a mid-cap winner too. However, after the stock's near-250% rally over the past three years, it's threatening to shed the mid-cap label as its market cap sits at $9.1 billion.Investors had a great chance in Okta stock when it reported earnings earlier this month. As investors reacted to the results, shares tumbled roughly 10% down to $70 per share. I flagged this as an overreaction before shares subsequently bounced back to the mid-$80s.Can we get another shot at Okta at lower price?If we get a market-wide correction, it's certainly possible. Last quarter, revenue grew almost 50% year-over-year, while earnings and sales came in ahead of expectations. Revenue expectations came in far ahead of expectations, although management guided for a larger-than-expected loss. * The 7 Best Penny Stocks to Buy At this point though, investors are willing to sacrifice the bottom line for top-line growth. That's no surprise, particularly as Okta nears break-even free cash flow. Revenue estimates now call for 34% growth this year and 30% growth next year. That's a solid run for Okta and it should allow dip buyers to cash in should management deliver. Box (BOX) Click to EnlargeThis one will draw some eye-rolls, but I still like Box (NASDAQ:BOX). The company makes cloud-management tools which has results in very consistent growth over the years. Unfortunately, that growth always seem to disappoint investors to an extent.Commanding a market cap of just $2.75 billion, that's less than four times this year's sales. That's actually pretty cheap among the cloud group. But is the CEO's seeming unwillingness to sell the company restricting that valuation? If he is, then to some extent I would say yes.Either way, Box has a solid enough business and a low enough valuation where investors shouldn't get too hurt owning the name. Analysts expect 15.4% revenue growth this year and 16% growth next year. Box is free-cash flow positive, as its net income hovers near break-even. Keep in mind, this stock was pushing $30 a share less than a year ago. If we can get another shot at this name at $17 or below, it may be a worthwhile investment.Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret Kenwell is long AMZN, BOX, NVTA and ROKU. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * The 7 Best Bond Funds to Buy for a Shift in Interest Rates * 10 Tech Stocks With Key Products That Face an Uncertain Future * 7 SaaS Stocks to Buy for Long-Term Gains Compare Brokers The post 7 Mid-Cap Growth Stocks That Could Be the Next Amazon or Netflix appeared first on InvestorPlace.
Biotech funds have stalled at key retracement levels after strong first quarter bounces and could sell off in the coming weeks, but small biotech stocks are still glued to the top of market performance lists, hitting new highs while posting outsized returns. It's wise to keep one eye on the research calendar when trading small biotech stocks with compounds in the pipeline, hitting the sidelines ahead of key dates because these issues can drop 50% or more overnight after adverse results. New York-based Axsome Therapeutics, Inc. (AXSM) researches and develops compounds and therapies for Alzheimer's disease and other central nervous system disorders.
Investment scams are nothing new. But since the dot-com bust of 2000, most investors have been able to spot the most egregious, misleading of corporate pitches.That's what's made the Theranos debacle such a shock. The blood-testing company looked, felt and sounded like the real deal. CEO Elizabeth Holmes seemed remarkably credible too… credible enough that insurers, pharmacies and grocery stores were all willing to partner with Theranos.The whole thing, however, was an incredible scam. The company's blood-based tests, as it turns out, couldn't do what Holmes had for years claimed they could. Their results were misleading at best and dangerously wrong at worst. Theranos is no defunct.InvestorPlace - Stock Market News, Stock Advice & Trading TipsNot surprisingly, Theranos' scandal has made investors skeptical of many similar diagnostic companies. * 7 Reasons to Buy Housing Stocks in 2019 That need not be the case, however. Theranos was the exception to the norm rather than the norm. There are many legitimate diagnostic companies, and one area that's seeing a huge boom is genomic testing. Genomic testing stocks belong to companies that look a person's -- or cancer's -- specific gene sequence in order to diagnose and treat patients. Here's a look at eight of the best of them. Exact Sciences (EXAS)Source: Shutterstock Exact Sciences (NASDAQ:EXAS) is committed to treating cancer by spotting it before it forms. Through its partnership with the Mayo Clinic, the company has developed diagnostic tools that can spot concerning colon cancer biomarkers from even the smallest DNA samples, identifying how vulnerable a particular person may be to cancer. In fact, you may be more familiar with the company than you realize. Exact Sciences is the name behind Cologuard, the colon-cancer screener that can be used at home rather than at a doctor's office of medical lab.Exact Sciences isn't yet profitable, but it's also not stopping at colon cancer. It's also working on screening tests that could identify liver, lung, breast and pancreatic cancers. More marketable tests means more revenue, which pushes the company closer to profitability. Genomic Health (GHDX)Source: Shutterstock Genomic Health (NASDAQ:GHDX) is arguably one of the quintessential genomic testing stocks. The company's Oncotype IQ tests allow doctors and caregivers to look at the specific nuances of a particular patient's cancer and tailor a specific treatment plan for that individual. More important, it works. And the medical community believes in what the company brings to the table.At this week's Gallen International Breast Cancer Conference, Dr. Joseph Gligorov of the Breast Cancer Expert Center at the APHP-Tenon Hospital in Paris commented:"The practice-changing precision made possible by such a test can lead to improved quality of care and survival among breast cancer patients, as well as reduced waste of healthcare resources by directing chemotherapy only to patients who have a high likelihood of deriving substantial benefit." * 3 Gold Stocks That Should Glitter With Rising Gold Prices So far the Oncotype battery is limited to breast, prostate and colon cancers, but more forms of cancer are on the radar. In the meantime, Genomic Health continues to refine its existing, proven tests. Sarepta Therapeutics (SRPT)Source: Shutterstock Sarepta Therapeutics (NASDAQ:SRPT) isn't exactly at home in a list of genomic testing stocks in that it's actually the developer of a treatment for Duchenne muscular dystrophy. Its therapy is gene-based, however, making the company more than relevant to investors that believe in the power of gene therapy. Its core product is Exondys 51 -- an injection that can cause a cell to 'skip' a faulty exon in RNA when replicating itself, restoring dystrophin production to functional levels. Dystrophin is a protein needed to make muscles function properly.Sarepta isn't stopping there, however. It's also working on an LGMD gene therapy that Janney analyst Yun Zhong has high hopes for. Zhong, in fact, believes Sarepta could double the size of the exon-skipping market by 2020. Crispr Therapeutics (CRSP)Source: Shutterstock Fans and followers of biotech developments have almost certainly heard the term 'CRISPR,' which is short for 'clustered regularly interspaced short palindromic repeats.' It's a family of DNA sequences that allow researchers and drug developers to manipulate longer spans of genetic material rather than repair one small segment of genetic material. Crispr Therapeutics (NASDAQ:CRSP) is one of the names that helped usher in the new way of thinking about gene-editing. Like Sarepta Therapeutics, it's arguably a little out of place in a look at genomic testing stocks to consider. But the biopharma outfit represents the best of the potential the industry sees for itself as it learns more about how DNA works (and doesn't work). * 10 Tech Stocks With Key Products That Face an Uncertain Future Crispr Therapeutics has already put the idea to good use too. Its pipeline includes treatments for hemoglobinopathies, some cancers, diabetes and other genetic diseases. InVitae (NVTA)InVitae (NYSE:NVTA) isn't exactly a household name, but perhaps someday it will be. The company makes a variety of genomics-based tests that help patients pinpoint potential problem ranging from heart trouble to cancer risks to neurological issues, just to name a few.And customers are buying them up, in spades. Last quarter's top line was up a whopping 117% year-over-year, with unit sales growing more than 100%.InVitae is still logging losses, but they're shrinking, and they're improving at an increasingly faster clip. This year's projected loss of $1.78 per share is only modestly better than last year's loss of $1.94 per share of NVTA stock. But, that loss is expected to be whittled down to only $1.15 per share next year -- on strong double-digit sales growth.InVitae is arguably the name investors are errantly looking past. Illumina (ILMN)Source: Flickr Whereas InVitae is the red-hot name few people have heard of, Illumina (NASDAQ:ILMN) is one of the genomic testing stocks most investors have heard of. The $45 billion behemoth is not only the name that's impossible to avoid, it's been largely deemed as the industry's standard-bearer. Illumina, in simplest terms, makes gene-sequencing and array technologies that can be utilized by drug developers or diagnostic companies. It's powering the genomic-testing market forward by empowering others. * Is This Overlooked Marijuana Stock a Buy? It's also, unlike most of its genomic-focused peers, profitable. Last quarter's revenue may have only grown 11% year-over-year. But, that top line of $867 million translated into earnings of $1.32 per share. For the full year, Illumina banked a profit of $5.72, which is expected to swell to $6.53 this year and $7.50 per share next year. Veracyte (VCYT)Source: Shutterstock Veracyte (NASDAQ:VCYT) currently offers three genomic tests. Afirma helps pin down thyroid cancers, Percepta helps doctors take aim at lung cancer and Envisia aids in the diagnosis of idiopathic pulmonary fibrosis. Like InVitae, Veracyte isn't yet profitable. But, also like InVitae, strong sales growth is quickly chipping away at its losses. Last year's loss of 62 cents per share is expected to shrink to a loss of only 41 cents per share of VCYT stock this year, and shrink to only 23 cents per share next year.Real profits are in sight, even if only on the distant horizon. Myriad Genetics (MYGN)Source: Shutterstock Finally, add Myriad Genetics (NASDAQ:MYGN) to a list of genomic testing stocks to consider. Myriad Genetics appropriately offers a myriad of genomic tests that can help patients and doctors look for genetic markers for everything ranging from breast cancer to depression to arthritis and more.And, like Illumina, Myriad Genetics is profitable. The $2.5 billion outfit turned $217 million worth of revenue last quarter, up 15%, into income of $6.1 million. Its hereditary cancer screener led the way. * The 7 Best Penny Stocks to Buy Growth appears to be in the cards too… perhaps much more than most investors fully appreciate. The medical community is fast-becoming a believer in the power of genetic testing, with the American Society of Breast Surgeons now recommending genetic testing for all breast cancer patients. Meanwhile, Medicare now covers Myriad's myPath(r) Melanoma test.As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can learn more about James at his site, jamesbrumley.com, or follow him on Twitter, at @jbrumley.Compare Brokers The post 8 Genomic Testing Stocks That Can Ease the Sting of Theranos appeared first on InvestorPlace.
Biotech stocks dominate our list of top charts to watch today. The stock is up over 50% this month, and over 400% since the start of the year, as investors await important clinical trial results on the company’s treatment for depression. Invitae Corp. (NVTA) rose 71 cents to $25.75 on 1.2 million shares Thursday.
The most recent earnings release Invitae Corporation's (NYSE:NVTA) announced in December 2018 revealed that losses became smaller relative to the prior year's level - great news for investors Below, I'veRead More...
SAN FRANCISCO, March 14, 2019 /PRNewswire/ -- Invitae Corporation (NVTA), a leading genetics company, today announced that Sean George, co-founder and chief executive officer of Invitae, will present at the Oppenheimer 29th Annual Healthcare Conference on Wednesday, March 20, 2019 at 1:35 p.m. Eastern / 10:35 a.m. Pacific in New York City. A live webcast of the presentation may be accessed by visiting the investors section of the company's website at ir.invitae.com. Invitae Corporation (NVTA) is a leading genetics company, whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people.
Investors are starting to warm up to those biotechnology companies developing treatments and diagnostics at the genetic level. Edidas Medicine (NASDAQ:EDIT) and CRISPR Therapeutics (NASDAQ:CRSP) were the hot stocks last year but faded in recent months. Conversely, Invitae (NASDAQ:NVTA) is hovering near 52-week highs, despite a $125 million recent equity offering of NVTA stock. Markets have much to like with this company.Invitae is in the business of genetic screening -- carrier screening, preimplantation genetic testing, prenatal testing, neonatal testing, and testing adult inherited diseases. In the last decade, it moved from niche, fragmented markets toward a single platform. The company grew from 229 samples in 2013 to more than 300,000 in 2018. This growth has afforded Invitae with two distinct advantages over its competitors.InvestorPlace - Stock Market News, Stock Advice & Trading TipsOne advantage is that by cutting the cost of goods sold to below $250, it delivers the highest quality testing at the most affordable price to its customers. The second advantage Invitae enjoys is the scalability of its business model. As the market grows, the company increases the number of patients that have their genetic information put to use. Combined with a falling cost profile as volume grows, the company is on track to reach a million samples next year in 2020. Strong Fourth-Quarter ResultsInvitae reported fourth-quarter revenue grew 78.6% to $45.4 million. GAAP EPS came in at a loss of 40 cents, which beat consensus estimates by 3 cents. For the year, volumes grew 102% to 303,000 samples. Exceeding its forecast of 285,000 samples, the company looks set to continue growing its revenue faster than costs. Chances are good that the company will report a profit sooner than expected. * 7 Dow Jones Stocks to Buy NVTA stock investors should take note that the company still needs to improve on its collection rates from third-party payers, including Medicare, and institutional and pharma partners. This group accounted for 23% of the company's 2018 revenues. In the fourth quarter, Invitae recognized $1.9 million in revenue from Medicare payments for Lynch syndrome. This is a result of catch up payments for tests that were done in the first half of 2018. Falling Costs Over the Long TermDeclining COGS is a good trend that Invitae investors like to see. COGS fell from $322 per sample in 2017 to $243 last quarter, down 24%. As the company invests in automation, this number will keep falling. Meanwhile, Invitae has enough demand from customers to keep prices at the same levels. It might even raise prices if customers are willing to pay for the introduction of new content and features. Conversely, adding new screening tests may limit the decrease in COGS in the near-term.Invitae expects that for the short-term, as it introduces an IPS, or non-invasive prenatal screening, cost of goods sold might go up. Once the test adoption phase ends, higher efficiencies and an increase in screening volume will drive costs lower.For 2019, Invitae management sees operating expenses increasing at first as the company invests to grow to 1 million patients. Still, the operating expenses will increase no more than the ~35% experienced in 2018. * 5 Airline Stocks In Serious Trouble Invitae expects to continue spending on sales and marketing, with much of the cost coming from the addition of 140 staff to the sales team. As expected for a growing firm, R&D activity will continue at similar levels to that of 2018. The Takeaway on NVTA StockWith cash, cash equivalents, restricted cash and marketable securities worth $131.9 million, why is the company selling $125 million worth of NVTA stock? Additional liquidity on the balance sheet will give the company plenty of operating flexibility as it carries out its growth. More importantly, Invitae stock's 52-week highs suggest the timing is favorable to sell shares when the market is willing to bid a higher price.Invitae has a solid business model that will lead to market share growth. Revenue is poised to keep growing at current rates, which is impressive. Invitae stock could face some profit-taking on concerns of valuation. Since NVTA stock trades close to analyst price targets, investors may continue holding on to this high-flying stock.Disclosure: As of this writing, the author did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Growth Stocks Racing to All-Time Highs * 5 Warren Buffett Stocks You Can't Go Wrong With * Game On for These 3 Gaming Stocks Compare Brokers The post Invitae Stock Is Hot Right Now And Here's Why It Will Only Get Hotter appeared first on InvestorPlace.
Quarterly earnings from around the industry suggested the epic growth opportunity isn't slowing down anytime soon.
NEW YORK, March 07, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
SAN FRANCISCO, March 6, 2019 /PRNewswire/ -- Invitae Corporation (NVTA) today announced the exercise in full of the underwriters' option to purchase an additional 1,350,000 shares of its common stock at the public offering price of $19.00 per share, in connection with Invitae's recently announced underwritten public offering of 9,000,000 shares of its common stock. As a result of the underwriters' option exercise, the aggregate gross proceeds to Invitae from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $196.7 million. J.P. Morgan Securities LLC, Cowen and Company, LLC and SVB Leerink LLC are acting as the book-running managers for the offering.
SAN FRANCISCO, March 5, 2019 /PRNewswire/ -- Invitae Corporation (NVTA) today announced the pricing of an underwritten public offering of 9,000,000 shares of its common stock at a price to the public of $19.00 per share. All of the shares are being sold by Invitae. The gross proceeds to Invitae from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be $171.0 million.